JP6793658B2 - Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物 - Google Patents

Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物 Download PDF

Info

Publication number
JP6793658B2
JP6793658B2 JP2017549093A JP2017549093A JP6793658B2 JP 6793658 B2 JP6793658 B2 JP 6793658B2 JP 2017549093 A JP2017549093 A JP 2017549093A JP 2017549093 A JP2017549093 A JP 2017549093A JP 6793658 B2 JP6793658 B2 JP 6793658B2
Authority
JP
Japan
Prior art keywords
phenyl
pyridazine
imidazo
difluoromethoxy
tetrahydropyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017549093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508554A (ja
JP2018508554A5 (cg-RX-API-DMAC7.html
Inventor
スティーブン・ティ・ロブレスキ
グレゴリー・ディ・ブラウン
リン・シューチュン
ジンウー・ドワン
ルー・ジョンホイ
ティ・ジー・ムラリ・ダール
ハイ−ユン・シャオ
アンドリュー・ジェイ・テベン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018508554A publication Critical patent/JP2018508554A/ja
Publication of JP2018508554A5 publication Critical patent/JP2018508554A5/ja
Application granted granted Critical
Publication of JP6793658B2 publication Critical patent/JP6793658B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017549093A 2015-03-18 2016-03-17 Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物 Active JP6793658B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562134779P 2015-03-18 2015-03-18
US62/134,779 2015-03-18
PCT/US2016/022738 WO2016149437A1 (en) 2015-03-18 2016-03-17 Tricyclic heterocyclic compounds useful as inhibitors of tnf

Publications (3)

Publication Number Publication Date
JP2018508554A JP2018508554A (ja) 2018-03-29
JP2018508554A5 JP2018508554A5 (cg-RX-API-DMAC7.html) 2019-04-25
JP6793658B2 true JP6793658B2 (ja) 2020-12-02

Family

ID=55640933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017549093A Active JP6793658B2 (ja) 2015-03-18 2016-03-17 Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物

Country Status (14)

Country Link
US (1) US10308652B2 (cg-RX-API-DMAC7.html)
EP (1) EP3271361B1 (cg-RX-API-DMAC7.html)
JP (1) JP6793658B2 (cg-RX-API-DMAC7.html)
KR (1) KR102630010B1 (cg-RX-API-DMAC7.html)
CN (1) CN107635992B (cg-RX-API-DMAC7.html)
AU (1) AU2016233289A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017019731A2 (cg-RX-API-DMAC7.html)
CA (1) CA2982446A1 (cg-RX-API-DMAC7.html)
EA (1) EA032314B1 (cg-RX-API-DMAC7.html)
ES (1) ES2797685T3 (cg-RX-API-DMAC7.html)
IL (1) IL254520A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017011433A (cg-RX-API-DMAC7.html)
SG (1) SG11201707471RA (cg-RX-API-DMAC7.html)
WO (1) WO2016149437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102696304B1 (ko) 2015-03-18 2024-08-16 브리스톨-마이어스 스큅 컴퍼니 Tnf의 억제제로서 유용한 헤테로시클릭 화합물
CA2980159A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
WO2016168638A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
WO2016168641A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Tricyclic modulators of tnf signaling
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CA2994703A1 (en) 2015-08-03 2017-02-09 Bristol-Myers Squibb Company Cyclic compounds useful as modulators of tnf alpha
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
JP7121033B2 (ja) 2017-03-15 2022-08-17 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391806A (en) * 1982-07-12 1983-07-05 The Dow Chemical Company Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators
DE69814049T2 (de) 1997-02-25 2004-02-19 The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
ES2254238T3 (es) * 1999-10-27 2006-06-16 Novartis Ag Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico.
WO2003064422A1 (en) 2002-01-31 2003-08-07 Daiichi Pharmaceutical Co., Ltd. IMIDAZO[1,2-a]PYRIDINE DERIVATIVE
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
US20110009403A1 (en) 2007-10-05 2011-01-13 S*Bio Pte Ltd. 2-morpholinylpurines as inhibitors of pi3k
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
ES2675583T3 (es) 2012-06-11 2018-07-11 Ucb Biopharma Sprl Bencimidazoles moduladores de TNF-alfa
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
BR112015000675B1 (pt) 2012-07-13 2022-07-12 UCB Biopharma SRL Derivados de imidazopiridina como moduladores da atividade de tnf
CA2888324A1 (en) * 2012-11-07 2014-05-15 Alexander Flohr Triazolo compounds
ES2529865B8 (es) * 2013-07-25 2016-01-22 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015086523A1 (en) 2013-12-09 2015-06-18 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
ES2809535T3 (es) 2013-12-09 2021-03-04 UCB Biopharma SRL Derivados de imidazopiridina como moduladores de la actividad de TNF
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2980464T3 (es) 2014-10-06 2024-10-01 Signal Pharm Llc Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos
CA2980159A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
KR102696304B1 (ko) 2015-03-18 2024-08-16 브리스톨-마이어스 스큅 컴퍼니 Tnf의 억제제로서 유용한 헤테로시클릭 화합물
WO2016168641A1 (en) * 2015-04-17 2016-10-20 Abbvie Inc. Tricyclic modulators of tnf signaling
MA42034A (fr) * 2015-05-04 2018-03-14 Actelion Pharmaceuticals Ltd Composés pipéridiniques tricycliques

Also Published As

Publication number Publication date
JP2018508554A (ja) 2018-03-29
SG11201707471RA (en) 2017-10-30
US10308652B2 (en) 2019-06-04
EP3271361A1 (en) 2018-01-24
BR112017019731A2 (pt) 2018-05-22
KR20170129811A (ko) 2017-11-27
CN107635992B (zh) 2020-05-22
CA2982446A1 (en) 2016-09-22
ES2797685T3 (es) 2020-12-03
EP3271361B1 (en) 2020-04-22
EA201792025A1 (ru) 2018-01-31
CN107635992A (zh) 2018-01-26
KR102630010B1 (ko) 2024-01-25
WO2016149437A1 (en) 2016-09-22
MX2017011433A (es) 2017-11-10
AU2016233289A1 (en) 2017-11-09
IL254520A0 (en) 2017-11-30
US20180111937A1 (en) 2018-04-26
EA032314B1 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
JP6793658B2 (ja) Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物
JP6982376B2 (ja) Ｒｏｒガンマ調節物質としての置換型テトラヒドロキノリン化合物
JP7299382B2 (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
JP6779899B2 (ja) Ｔｎｆ阻害剤として有用なヘテロ環式化合物
US20240182490A1 (en) Bromodomain inhibitors
JP6793657B2 (ja) 置換三環式ヘテロ環式化合物
JP2021193099A (ja) 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
CA3085561A1 (en) Cyclohexyl acid triazole azines as lpa antagonists
JP6811233B2 (ja) Ｔｎｆアルファの修飾因子として有用な環状化合物
JP7612662B2 (ja) （ヘテロ）アリール－メチル－チオ－ベータ－ｄ－ガラクトピラノシド誘導体
WO2007032466A1 (ja) 複素環化合物、その製造方法並びに用途
JP2019512534A (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
WO2016063080A1 (en) Indazole and indole derivatives as inhibitors of retinoic acid relates orphan receptor gamma (ror gamma) for the treatment of immune-related diseases
JP2025520081A (ja) Ｔｒｐｍ３媒介性障害を治療するためのインドリジン誘導体
TW202425978A (zh) C5ar1拮抗劑及其用途
JP2025517512A (ja) Ｔｒｐｍ３媒介性障害を治療するための新たな誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190315

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201013

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201110

R150 Certificate of patent or registration of utility model

Ref document number: 6793658

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250